Pharmaceutical Executive December 22, 2025
Key Takeaways
- Alnylam’s $250 million investment will enhance its Norton, Massachusetts facility with an enzymatic ligation platform to meet global RNAi therapeutics demand.
- The expansion supports Alnylam’s pipeline for siRNA treatments targeting diseases such as hypertension, type 2 diabetes, and obesity.
- Massachusetts leaders highlight the state’s role in biomanufacturing, emphasizing job creation and local production of innovative medicines.
- Alnylam’s board changes include the departure of Mike Bonney and Carolyn Bertozzi, with Stuart Arbuckle joining in 2026.
The investment will allow the facility to meet the growing demand for RNAi therapeutics.
Alnylam will invest $250 million in its US manufacturing facility in order to increase its ability to meet the growing global demand for RNAi therapeutics.1 Specifically, this investment...
Today's Sponsors
Today's Sponsor